Search by Abstract Number Results

Abstract Number: 0369 • ACR Convergence 2024
Can Treatment Expectations or Treatment Itself in Patients with Arthralgia Suspicious for Progression to Rheumatoid Arthritis Improve Illness Perceptions?
Simonetta van Griethuysen¹, Quirine Dumoulin² and Annette van der Helm-van Mil³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Negative Illness perceptions (IPs) are associated with poorer disease outcomes in rheumatoid arthritis (RA). Unfortunately, IPs are generally fixed in established RA. We hypothesized…
Abstract Number: 0369 • ACR Convergence 2023
Trajectory of Progression in Transition Readiness in Adolescents with JIA and jSLE
Dorota Borovsky¹, Lauren Heessels¹, Tania Cellucci², Liane Heale¹, Julie Herrington¹, KAREN BEATTIE¹ and Michelle Batthish², ¹McMaster University, Hamilton, ON, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: For adolescents, the transition from pediatric to adult rheumatology care is associated with increased health risks, poor disease control and loss to follow-up. Optimizing…
Abstract Number: 0369 • ACR Convergence 2022
The Longitudinal Measurement Properties and Clinical Application of the PROMIS Fatigue 13a and 10a in Lupus
Paul Kamudoni¹, Alexandra Lauer¹, Oliver Guenther¹, Cristina Vazquez Mateo² and Karon Cook³, ¹the healthcare business of Merck KGaA, Darmstadt, Germany, ²Global Clinical Development, EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ³Feral Scholars, Broaddus, TX
Background/Purpose: Fatigue is among the most prevalent symptoms of systemic lupus erythematosus (SLE) and is associated with patient distress, work dysfunction, and worse overall health…
Abstract Number: 0369 • ACR Convergence 2021
High Frequency of Complications in Axial Spondyloarthropathy Pregnancies: Emerging Data from the Ankylosing Spondylitis Registry of Ireland
Sinead Maguire¹, Phil Gallagher² and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²St Vincent's Hospital, Dublin, Ireland
Background/Purpose: National registries are excellent sources of data to allow analysis of inflammatory arthritis such as axial spondyloarthropathy (axSpA). Our understanding of axSpA has evolved…
Abstract Number: 0369 • ACR Convergence 2020
Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs
Atul Deodhar¹, Xenofon Baraliakos², Iain McInnes³, Kurt de Vlam⁴, Louis Bessette⁵, Anna Maniccia⁶, Ralph Lippe⁷, Christopher Saffore⁶, Tianming Gao⁶, In-Ho Song⁶ and Andrew Östör⁸, ¹Oregon Health & Science University, Portland, OR, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ³Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, ⁵Laval University, Quebec, Canada, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸Cabrini Medical Center, Monash University, Malvern, Victoria, Australia
Background/Purpose: Pain is a debilitating symptom of ankylosing spondylitis (AS) and negatively impacts patient (pt) lives. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor engineered for…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].